Drugs / lactobacillus CD2 lozenges
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01480011 | Nov 2011 → Sep 2012 | chemotherapy-induced oral mucositis | All India Institute of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lactobacillus CD2 lozenges | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01480011 ↗ |
| Known as | L. brevis CD2 | “L. brevis CD2 lozenges reduced the incidence of grade III and IV anticancer therapy-induced oral mucositis” PMID 21741230 ↗ Jul 2011 |
| Route | Oral | “Eligible patients received four to six lozenges of L. brevis CD2 per day” PMID 28848667 ↗ Feb 2017 |